NK cell therapy for relapsed or refractory AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have AML that has relapsed or not responded to treatment.
- Your leukemia cells must have the CLL1 protein.
- You must be well enough to perform daily activities (ECOG score 0 or 1).
- You must not have had a stem cell transplant from another person.
- You must not have active central nervous system leukemia or certain other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This early-phase study tests whether a treatment using NK cells plus monoclonal antibodies is safe and effective for adults with relapsed or hard-to-treat acute myeloid leukemia (AML). It’s mainly looking for safety, and whether the treatment can help control the leukemia.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new treatment made from your own immune cells (NK cells) that are modified to recognize and attack cancer cells with a marker called CD7. It is for people whose blood cancer has returned or not improved with other treatments.
This trial tests a type of immune cell (CAR NK cells) that targets a protein called CD33 on leukemia cells. It is for children and young adults with AML that has relapsed or not responded to treatment.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.